TABLE 2.
Descriptive information
| [18F]altanserin (n = 154) | [11C]Cimbi‐36 (n = 43) | |||||
|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | Mean ± SD | Median | Range | |
| Age (years) | 40.76 ± 17.97 | 35.10 | 18.47–81.73 | 26.84 ± 5.81 | 26.42 | 18.43–49.82 |
| BMI (kg/m2) | 25.51 ± 4.70 | 24.44 | 18.38–45.91 | 23.86 ± 2.84 | 23.08 | 19.32–33.20 |
| Inj. dose a (MBq) | 275.19 ± 64.83 | 278.00 | 143.00–447.00 | 497.74 ± 100.62 | 511.12 | 213.00–604.04 |
| SA a (GBq/μmol) | 76.14 ± 62.32 | 55.71 | 10.30–357.78 | 345.13 ± 243.01 | 273.14 | 73.36–1,039.63 |
| Inj. mass a (μg) | 2.84 ± 2.22 | 2.12 | 0.26–10.99 | 0.84 ± 0.48 | 0.75 | 0.11–1.50 |
| Neocortical binding b | 1.46 ± 0.56 | 1.47 | 0.32–4.66 | 1.30 ± 0.21 | 1.28 | 0.99–2.02 |
| PET scanner (GE/HRRT) | 142/12 | 0/43 | ||||
| MR field strength (1.5 T/3 T) | 63/91 (1.5 T: Siemens Vision 3 T: Siemens Magnetom Trio) | 0/43 (3 T: Siemens Prisma, Siemens Magnetom Verio) | ||||
| Sex (m/f) | 94/60 | 25/18 | ||||
Abbreviations: BMI, body mass index; HRRT, High Resolution Research Tomograph; Inj., injected (dose/mass); MR, magnetic resonance; PET, Positron emission tomography; SA, specific activity; SD, standard deviation.
a
Inj. dose: n = 129/43; SA: n = 81/43; Inj. mass: n = 77/43 ([18F]altanserin/[11C]Cimbi‐36).
b
[18F]altanserin: BPP; [11C]Cimbi‐36: BPND.